Potential therapeutic targets in plasma cell disorders: A flow cytometry study

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Robust isolation of malignant plasma cells in multiple myeloma

(2014) I. Frigyesi et al.   BLOOD

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

(2014) Balaji Balasa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Brentuximab vedotin: An anti-CD30 antibody-drug conjugate

(2013) A. M. Bradley et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma

(2013) Juan J. Gu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study

(2013) Wenli Zheng et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

CD30: from basic research to cancer therapy

(2013) Hiromi Muta et al.   IMMUNOLOGIC RESEARCH

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome

(2013) Gang An et al.   LEUKEMIA RESEARCH

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

(2012) B Paiva et al.   LEUKEMIA

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

(2011) T. Bochtler et al.   BLOOD

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

Immunophenotyping in multiple myeloma and related plasma cell disorders

(2010) Shaji Kumar et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders

(2010) Karthick R. M. Raja et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma

(2010) Hans E. Johnsen et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

(2009) Akihiro Takeshita et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunophenotype of neoplastic plasma cells in AL amyloidosis

(2009) M Deshmukh et al.   JOURNAL OF CLINICAL PATHOLOGY

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH